Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of sexually transmitted diseases
3.2.1.2 Growing awareness and screening programs
3.2.1.3 Increasing research and development activities
3.2.1.4 Technological advancements in STD diagnostics
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stigma and sociocultural barriers
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Instrument/analyzers
5.2.1 Laboratory devices
5.2.1.1 Thermal cyclers – PCR
5.2.1.2 Lateral flow readers
5.2.1.3 Flow cytometers
5.2.1.4 Absorbance microplate reader
5.2.1.5 Differential light scattering machines
5.2.1.6 Other laboratory devices
5.2.2 Point of care devices
5.2.2.1 Phone chips (Microfludics + ICT)
5.2.2.2 Portable/bench top/rapid diagnostic kits
5.3 Consumables
Chapter 6 Market Estimates and Forecast, By Test Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Laboratory testing
6.3 Point of care (PoC) testing
Chapter 7 Market Estimates and Forecast, By Disease, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
7.3 Syphilis
7.4 Gonorrhea
7.5 Genital herpes (HSV I & HSV II)
7.6 HPV (Human papillomavirus)
7.7 HIV/AIDS (Human immunodeficiency virus/ acquired immunodeficiency syndrome)
7.8 Ureaplasma & mycoplasma
7.9 Trichomoniasis
7.10 VZV (Varicella zoster virus)
7.11 Other diseases
Chapter 8 Market Estimates and Forecast, By Technology, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Immunoassay
8.3 Molecular diagnostics
8.4 Other technologies
Chapter 9 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Diagnostic laboratories
9.4 Home care testing
9.5 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Abbott Laboratories
11.2 Becton, Dickinson and Company
11.3 bioMerieux SA
11.4 Bio-Rad Laboratories, Inc.
11.5 Danaher Corporation
11.6 F. Hoffmann-La Roche Ltd
11.7 Hologic, Inc.
11.8 QIAGEN N.V.
11.9 Seegene Inc.
11.10 Siemens Healthineers AG
11.11 Thermo Fisher Scientific Inc.
11.12 Trinity Biotech plc
